Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Privigen in Primary Immunodeficiency
NCT00168025Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Sep 2004
01
Overview
Phase 3, open-label, single-arm trial of intravenous immunoglobulin G in primary immunodeficiency (PI), sponsored by CSL Limited. Primary endpoint: Annualized rate of acute serious bacterial infections. Started Sep 2004; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT00168025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168025.